A phase II study of tislelizumab (TIS) and chemotherapy as neoadjuvant therapy for potentially resectable stage IIIA/IIIB non-small cell lung cancer (NSCLC)

被引：0
|
作者：
Wang, Ting
Huang, Lu Li Lin
Liu, Jie Wei
Zhu, Da Xing
Dong, Jing Si
Deng, Han Yu
Zheng, Xi
Tian, Long
Jiang, Li Li
Wang, Wei Ya
Zhou, Ping
Su, Ming Gang
Pu, Dan
Cai, Xu Yu
Feng, Ming Yang
Ou, Xue Jin
Wang, Yongsheng
Zhou, Qing Hua
机构：
[1] Sichuan Univ, West China Hosp, Dept Thorac Surg, Chengdu, Peoples R China
[2] Sichuan Univ, West China Hosp, Lung Canc Ctr, Chengdu, Peoples R China
[3] Sichuan Univ, West China Hosp, Dept Pathol, Chengdu, Peoples R China
[4] Sichuan Univ, West China Hosp, Dept Nucl Med, Chengdu, Peoples R China
[5] Sichuan Univ, West China Hosp, Ctr Canc, Thorac Oncol Ward, Chengdu, Peoples R China
[6] Sichuan Univ, West China Hosp, Chengdu, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
8024
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Neoadjuvant chemoimmunotherapy in resectable stage IIIA/IIIB non-small cell lung cancer
    Chen, Yulong
    Yan, Bo
    Xu, Feng
    Hui, Zhenzhen
    Zhao, Gang
    Liu, Jie
    Zhang, Huan
    Zeng, Ziqing
    Zhang, Ran
    Provencio, Mariano
    Ren, Xiubao
    You, Jian
    TRANSLATIONAL LUNG CANCER RESEARCH, 2021, 10 (05) : 2193 - +
  • [2] Neoadjuvant camrelizumab combined with chemotherapy for resectable stage IIIA-IIIb non-small cell lung cancer: Single arm phase II study
    Cai, Guoxin
    Wang, Kaiyue
    Wang, Xiaohan
    Zhao, Jiarui
    Han, Xiao
    Zhou, Haiyan
    Xie, Chao
    Jia, Hui
    Fu, Shuai
    Huang, Yong
    Li, Wanhu
    Teng, Feifei
    Wang, Suzhen
    Yu, Jinming
    Song, Pingping
    Meng, Xue
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [3] Neoadjuvant Camrelizumab Combined with Chemotherapy for Resectable Stage IIIA-IIIB Non-Small Cell Lung Cancer: Single Arm Phase II Study
    Cai, G.
    Wang, K.
    Wang, X.
    Zhao, J.
    Wang, Z.
    Han, X.
    Zhou, H.
    Xie, C.
    Fu, S.
    Hui, J.
    Huang, Y.
    Li, W.
    Teng, F.
    Wang, S.
    Yu, J.
    Song, P.
    Meng, X.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2024, 120 (02): : E10 - E10
  • [4] Neoadjuvant Sintilimab and Chemotherapy for Resectable Stage IIIA Non-Small Cell Lung Cancer
    Zhang, Peng
    Dai, Jie
    Sun, Fenghuan
    Xia, Haoran
    He, WenXin
    Duan, Liang
    Liu, Ming
    Zhao, Deping
    Zhu, Yuming
    Jiang, Gening
    ANNALS OF THORACIC SURGERY, 2022, 114 (03): : 949 - 958
  • [5] Non-small cell lung cancer (NSCLC) stage IIIA/IIIB. A pilot study of neoadjuvant chemotherapy with paclitaxel and carboplatin
    Ukena, D
    Leutz, M
    Schlimmer, P
    Huwer, H
    Schafers, HJ
    Sybrecht, G
    MEDIZINISCHE KLINIK, 1997, 92 : 49 - 53
  • [6] Pathological Response to Neoadjuvant Tislelizumab Plus Chemotherapy in Potentially Resectable Stage IIIB NSCLC
    Wang, T.
    Wang, P. -L.
    Song, Y. -X.
    Chen, H.
    Li, L.
    Wang, Y.
    Ding, L. -R.
    Huang, X. -J.
    Zheng, B.
    Zhang, J. -R.
    Liu, J. -W.
    Zhu, D. -X.
    Tian, L.
    Jiang, L. -L.
    Zhou, P.
    Su, M. -G.
    Pu, D.
    Jiang, R.
    Huang, K. -L.
    Wang, Y. -S.
    Chen, C.
    Zhou, Q. -H.
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S570 - S571
  • [7] Phase II Trial of Neoadjuvant Tislelizumab with Chemotherapy for Resectable Stage IIB-III Non-small Cell Lung Cancer
    Lin, Y-B
    Long, H.
    Chen, Y-H
    Zhai, W-Y
    Wang, Y-Z
    Rao, B-Y
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S287 - S287
  • [8] Experience with neoadjuvant chemotherapy in stage IIIa non-small cell lung carcinoma (NSCLC).
    González, MB
    Valdivia, J
    Ortega, JA
    Delgado, JR
    Ballesteros, P
    Martinez, A
    Belón, J
    EUROPEAN JOURNAL OF CANCER, 1999, 35 : S71 - S71
  • [9] Efficacy and safety of neoadjuvant chemoimmunotherapy and chemotherapy in patients with potentially resectable stage IIIA/IIIB NSCLC: a retrospective study
    Wang, Yuchen
    Ma, Xiaobo
    Ma, Kewei
    Chen, Xi
    He, Hua
    Zhao, Xiangye
    Fan, Mengge
    Xu, Yinghui
    FRONTIERS IN IMMUNOLOGY, 2025, 15
  • [10] BGB-LC-202 (NCT05577702): Phase II Umbrella study of tislelizumab (TIS) monotherapy and TIS-based immunotherapy combinations plus /- chemotherapy (CT) as neoadjuvant treatment in Chinese patients (pts) with resectable stage II to IIIA non-small cell lung cancer (NSCLC)
    He, J.
    Zhang, P.
    Liu, H.
    Liang, W.
    Yu, W.
    Shi, J.
    Wei, B.
    Zheng, W.
    Shen, Z.
    Wu, N.
    ANNALS OF ONCOLOGY, 2023, 34 : S1652 - S1653
12345